Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claim 1. (Currently amended) A system comprising capreomycin and a device for introducing ~~said~~ the capreomycin into gases for inhalation by a person in need thereof.

Claim 2. (Currently amended) ~~A~~ The system of claim 1, wherein ~~said~~ the capreomycin is introduced into ~~said~~ the gases as a solution, a suspension, a powder, or a spray.

Claim 3. (Currently amended) ~~A~~ The system of claim 1, wherein ~~said~~ the device is a nebulizer, a metered dose inhaler, or a dry powder inhaler.

Claim 4. (Currently amended) ~~A~~ The system of claim 3, wherein ~~said~~ the nebulizer is selected from the group consisting of a heated nebulizer, an ultrasonic nebulizer, a gas nebulizer, a venturi nebulizer, and a refillable nebulizer.

Claim 5. (Currently amended) ~~A~~ The system of claim 1, wherein ~~said~~ the capreomycin is introduced into ~~said~~ the gases in an average particle size of between 1 and 10 microns.

Claim 6. (Currently amended) ~~A~~ The system of claim 5, wherein ~~said~~ the capreomycin has an average particle size of between 2 and 6 microns.

Claim 7. (Currently amended) ~~A~~ The system of claim 5, wherein ~~said~~ the capreomycin has an average particle size of about 3 to about 5 microns.

Claim 8. (Currently amended) ~~A~~ The system of claim 1, wherein ~~said~~ the capreomycin is provided as a powder.

Claim 9. (Currently amended) ~~A~~ The system of claim 8, wherein ~~said~~ the capreomycin is introduced into ~~said~~ the gases in an average particle size of between 1 and 10 microns.

Claim 10. (Currently amended) ~~A~~ The system of claim 9, wherein ~~said~~ the capreomycin has an average particle size of about 3 to about 5 microns.

Claim 11. (Original) A formulation of capreomycin suitable for aerosol administration.

Claim 12. (Currently amended) ~~A~~ The formulation of capreomycin of claim 11, wherein ~~said~~ the capreomycin has an average particle size between 1 and 10 microns.

Claim 13. (Currently amended) ~~A~~ The formulation of capreomycin of claim 12, wherein ~~said~~ the capreomycin is complexed or associated with a polysaccharide.

Claim 14. (Currently amended) A method of inhibiting the growth of *Mycobacterium tuberculosis* ("MTB"), ~~said~~ the method comprising the step of introducing capreomycin into gases to be inhaled by a patient in need thereof.

Claim 15. (Currently amended) ~~A~~ The method of claim 14, wherein ~~said~~ the capreomycin is introduced into ~~said~~ the gases as a solution, a suspension, a powder, or a spray.

Claim 16. (Currently amended) ~~A~~ The method of claim 14, wherein ~~said~~ the capreomycin introduced into ~~said~~ the gases in an average particle size of between 1 and 10 microns.

Claim 17. (Currently amended) ~~A~~ The method of claim 14, wherein ~~said~~ the capreomycin is complexed or associated with a polysaccharide.

Claim 18. (Currently amended) ~~A~~ The method of claim 14, wherein ~~said~~ the capreomycin is introduced into ~~said~~ the gases by a nebulizer, a metered dose inhaler, or a dry powder inhaler.

Claim 19. (Currently amended) ~~A~~ The method of claim 18, wherein ~~said~~ the nebulizer is selected from the group consisting of a heated nebulizer, an ultrasonic nebulizer, a gas nebulizer, a venturi nebulizer, and a refillable nebulizer.

Claim 20. (Currently amended) A method of inhibiting the growth of *Mycobacterium tuberculosis* ("MTB") in a patient, ~~said~~ the method comprising the step of administering to a lung of ~~said~~ the patient aerosolized capreomycin, wherein ~~said~~ the capreomycin inhibits the growth of MTB in ~~said~~ the patient.

Claim 21. (Currently amended) ~~A~~ The method of claim 20, wherein ~~said~~ the capreomycin is administered to ~~said~~ the lung as a solution, a suspension, a powder, or a spray.

Claim 22. (Currently amended) ~~A~~ The method of claim 20, wherein ~~said~~ the capreomycin is administered to said lung by a nebulizer, a metered dose inhaler, or a dry powder inhaler.

Claim 23. (Currently amended) ~~A~~ The method of claim 22, wherein ~~said~~ the nebulizer is selected from the group consisting of a heated nebulizer, an ultrasonic nebulizer, a gas nebulizer, a venturi nebulizer, and a refillable nebulizer.

Claim 24. (Currently amended) ~~A~~ The method of reducing infectivity of a person infected with *Mycobacterium tuberculosis* ("MTB"), ~~said~~ the method comprising the step of administering to the lung of ~~said~~ the person aerosolized capreomycin, wherein ~~said~~ the capreomycin reduces the infectivity of ~~said~~ the person.

Claim 25. (Currently amended) ~~A~~ The method of claim 24, wherein ~~said~~ the capreomycin is administered to ~~said~~ the lung as a solution, a suspension, a powder, or a spray.

Claim 26. (Currently amended) ~~A~~ The method of claim 24, wherein ~~said~~ the capreomycin is administered to ~~said~~ the lung by a nebulizer, a metered dose inhaler, or a dry powder inhaler.

Claim 27. (Currently amended) ~~A~~ The method of claim 26, wherein ~~said~~ the nebulizer is selected from the group consisting of a heated nebulizer, an ultrasonic nebulizer, a gas nebulizer, a venturi nebulizer, and a refillable nebulizer.

Claim 28. (Original) A use of capreomycin for manufacture of a medicament for aerosolized administration to a lung as a solution, a suspension, a powder, or a spray.

Claim 29. (Currently amended). ~~A~~ The use of claim 28, wherein ~~said~~ the medicament is suitable for delivery to ~~said~~ the lung by a nebulizer, a metered dose inhaler, or a dry powder inhaler.

Claim 30. (Original) A formulation of lyophilized capreomycin having an average particle size of from about 1 to about 10 microns.